![John Orloff](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
John Orloff
Keine laufenden Positionen mehr
Vermögen: - $ am 30.06.2026
Profil
Gegenwärtig ist John J. Orloff Executive VP, Head-Research & Development bei Alexion Pharmaceuticals, Inc. In der Vergangenheit war er Director bei Novelion Therapeutics, Inc. und Executive Vice President & Head-Research bei Aegerion Pharmaceuticals, Inc. sowie Chief Scientific Officer, EVP, Global Head-R&D bei Baxalta, Inc. und Vice President, Global Head-Research & Development bei Baxter BioScience Corp. sowie Chief Medical Officer & Senior Vice President der Novartis Pharma AG. Dr. Orloff erwarb einen Bachelor-Abschluss am Dartmouth College und einen Doktortitel am University of Vermont College of Medicine.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
-.--% | 15.06.2026 | 0 ( -.--% ) | - $ | 30.06.2026 |
Aktive Positionen von John Orloff
| Unternehmen | Position | Beginn |
|---|---|---|
Agent Capital LLC
 Agent Capital LLC Investment ManagersFinance Agent Capital invests in companies located in the United States. The firm targets companies operating in the fields of therapeutics sectors and industries. It provides financing for seed, early, late stage, crossover and PIPE stage requirements. The firm acts as a lead investor and also makes co-investments. | Private Equity Investor | 01.10.2021 |
Zenas Pharma, Inc.
 Zenas Pharma, Inc. BiotechnologyHealth Technology Develops and markets immunology based therapies for patients | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von John Orloff
| Unternehmen | Position | Ende |
|---|---|---|
| BENEVOLENTAI S.A. | Direktor/Vorstandsmitglied | 16.10.2024 |
BenevolentAI Ltd.
 BenevolentAI Ltd. Packaged SoftwareTechnology Services Operates as a AI-enabled drug discovery company | Direktor/Vorstandsmitglied | 01.10.2024 |
| ALEXION PHARMACEUTICALS, INC. | Technik-/Wissenschafts-/F&E-Leiter | 21.07.2021 |
| NOVELION THERAPEUTICS INC. | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2017 |
| BAXALTA INC | Technik-/Wissenschafts-/F&E-Leiter | 01.06.2016 |
Ausbildung von John Orloff
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
63
Beziehungen ersten Grades
13
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 13 |
|---|---|
Alexion Pharmaceuticals, Inc.
 Alexion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops life-changing therapies for people living with rare disorders | Health Technology |
Aegerion Pharmaceuticals, Inc.
 Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops and commercializes therapies for hyperlipidemia and metabolic diseases | Health Technology |
Baxalta, Inc.
 Baxalta, Inc. Pharmaceuticals: MajorHealth Technology Engages in research, development and manufacture of therapies and biopharmaceutical products | Health Technology |
Dartmouth College
 Dartmouth College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Baxter BioScience Corp.
 Baxter BioScience Corp. BiotechnologyHealth Technology Provides biopharmaceutical and vaccines services | Health Technology |
Merck Research Laboratories Massachusetts LLC
 Merck Research Laboratories Massachusetts LLC Pharmaceuticals: MajorHealth Technology Discovers, develops, and markets a broad range of human and animal health products | Health Technology |
Novartis Pharma AG
 Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company | Health Technology |
University of Vermont College of Medicine
 University of Vermont College of Medicine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Novelion Therapeutics, Inc.
 Novelion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops, manufactures and markets rare disease products, metreleptin and lomitapide | Health Technology |
BenevolentAI Ltd.
BenevolentAI Ltd. Packaged SoftwareTechnology Services Operates as a AI-enabled drug discovery company | Technology Services |
Agent Capital LLC
Agent Capital LLC Investment ManagersFinance Agent Capital invests in companies located in the United States. The firm targets companies operating in the fields of therapeutics sectors and industries. It provides financing for seed, early, late stage, crossover and PIPE stage requirements. The firm acts as a lead investor and also makes co-investments. | Finance |
BenevolentAI SA
 BenevolentAI SA Packaged SoftwareTechnology Services Develops AI drug discovery platform to accelerate biopharma drug discovery | Technology Services |
Zenas Pharma, Inc.
Zenas Pharma, Inc. BiotechnologyHealth Technology Develops and markets immunology based therapies for patients | Health Technology |
Wählen Sie MarketScreener 
